**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 401/00 | A2

(11) International Publication Number: WO 00/08013

(43) International Publication Date: 17 February 2000 (17.02.00)

(21) International Application Number: PCT/IB99/01239

(22) International Filing Date: 5 July 1999 (05.07.99)

(30) Priority Data:
PCT/IB98/01206 6 August 1998 (06.08.98) IB

(71) Applicant *(for JP only)*: PFIZER PHARMACEUTICALS INC. [JP/JP]; Mitsui Building, 1–1, Nishi–shinjuku 2–chome, Shinjuku–ku, Tokyo 163 (JP).

(71) Applicant *(for all designated States except JP US)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: ITO, Fumitaka [JP/JP]; Pfizer Pharmaceuticals Inc., Central Research Nagoya, 2, Aza 5–gochi, Taketoyo–cho, Chita–gun, Aichi–ken 470–2393 (JP). NOGUCHI, Hirohide [JP/JP]; Pfizer Pharmaceuticals Inc., Central Research Nagoya, 2, Aza 5–gochi, Taketoyo–cho, Chita–gun, Aichi–ken 470–2393 (JP). KONDO, Hiroshi [JP/JP]; Pfizer Pharmaceuticals Inc., Central Research Nagoya, 2, Aza 5–gochi, Taketoyo–cho, Chita–gun, Aichi–ken 470–2393 (JP).


(74) Agents: SPIEGEL, Allen, J. et al.; c/o Simpson, Alison, Urquhart–Dykes & Lord, 91 Wimpole Street, London W1M 8AH (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published**

*Without international search report and to be republished upon receipt of that report.*

(54) Title: 2–SUBSTITUTED–1–PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1–RECEPTOR AGONISTS




(57) Abstract

A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is unsubstituted, mono–, di– or tri–substituted ($C_3$–$C_{11}$)cycloalkyl or ($C_3$–$C_{11}$)cycloalkenyl or the like, A is unsubstituted ($C_1$–$C_7$)alkyl or ($C_2$–$C_5$)alkenyl, or unsubstituted, mono–, di– or tri–substituted aryl, or aromatic–heterocyclic or the like, Y is hydrogen, halo, amino or mercapto, or unsubstituted, mono–, di– or tri–substituted ($C_1$–$C_{10}$)alkyl–M–, ($C_3$–$C_7$)cycloalkyl–M–, ($C_2$–$C_6$)alkenyl–M–, ($C_1$–$C_4$)alkyl–NH–(($C_1$–$C_4$)alkyl)–M–, di($C_1$–$C_4$)alkyl–N–(($C_1$–$C_4$)alkyl)–M–, aryl–M–, aromatic or non–aromatic heterocyclic–M–, aryl–($C_1$–$C_5$)alkyl–M– or aromatic non–aromatic heterocyclic–($C_1$–$C_5$)alkyl–M–, wherein M is a covalent bond O, S, NH or the like, or the like; $Z^1$, $Z^2$, $Z^3$ and $Z^4$ are hydrogen or the like, has ORL1–receptor agonist activity, and are useful as analgesics or the like in mammalian subjects.